Skip to main content
Top
Published in: European Radiology 7/2018

01-07-2018 | Interventional

Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival

Authors: Marco Calandri, Suguru Yamashita, Carlo Gazzera, Paolo Fonio, Andrea Veltri, Sara Bustreo, Rahul A. Sheth, Steven M. Yevich, Jean-Nicolas Vauthey, Bruno C. Odisio

Published in: European Radiology | Issue 7/2018

Login to get access

Abstract

Objectives

To investigate effects of ablation margins on local tumour progression-free survival (LTPFS) according to RAS status in patients with colorectal liver metastases (CLM).

Methods

This two-institution retrospective study from 2005–2016 included 136 patients (91 male, median age 60 years) with 218 ablated CLM. LTPFS was performed using the Kaplan–Meier method and evaluated with the log-rank test. Uni/multivariate analyses were performed using Cox-regression models.

Results

Three-year LTPFS rates for CLM with minimal ablation margin ≤10 mm were significantly worse than those with >10 mm in both mutant-RAS (29% vs. 48%, p=0.038) and wild-type RAS (70% vs. 94%, p=0.039) subgroups. Three-year LTPFS rates of mutant-RAS were significantly worse than wild-type RAS in both CLM subgroups with minimal ablation margin ≤10 mm (29% vs. 70%, p<0.001) and >10 mm (48% vs. 94%, p=0.006). Predictors of worse LTPFS were ablation margins ≤10 mm (HR: 2.17, 95% CI 1.2–4.1, p=0.007), CLM size ≥2 cm (1.80, 1.1–2.8, p=0.017) and mutant-RAS (2.85, 1.7–4.6, p<0.001).

Conclusions

Minimal ablation margin and RAS status interact as independent predictors of LTPFS following CLM ablation. While minimal ablation margins >10 mm should be always the procedural goal, this becomes especially critical for mutant-RAS CLM.

Key Points

RAS and ablation margins are predictors of local tumour progression-free survival.
Ablation margin >10 mm, always desirable, is crucial for mutant RAS metastases.
Interventional radiologists should be aware of RAS status to optimize LTPFS.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shady W, Petre EN, Gonen M et al (2016) Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center. Radiology 278:601–611.CrossRefPubMed Shady W, Petre EN, Gonen M et al (2016) Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center. Radiology 278:601–611.CrossRefPubMed
2.
go back to reference de Baere T, Tselikas L, Yevich S et al (2017) The role of image-guided therapy in the management of colorectal cancer metastatic disease. Eur J Cancer 75:231–242.CrossRefPubMed de Baere T, Tselikas L, Yevich S et al (2017) The role of image-guided therapy in the management of colorectal cancer metastatic disease. Eur J Cancer 75:231–242.CrossRefPubMed
3.
go back to reference Solbiati L, Ahmed M, Cova L et al (2012) Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 265:958–968. CrossRefPubMed Solbiati L, Ahmed M, Cova L et al (2012) Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 265:958–968. CrossRefPubMed
4.
go back to reference Sofocleous CT, Petre EN, Gonen M et al (2011) CT-guided Radiofrequency Ablation as a Salvage Treatment of Colorectal Cancer Hepatic Metastases Developing after Hepatectomy. J Vasc Interv Radiol 22:755–761. CrossRefPubMedPubMedCentral Sofocleous CT, Petre EN, Gonen M et al (2011) CT-guided Radiofrequency Ablation as a Salvage Treatment of Colorectal Cancer Hepatic Metastases Developing after Hepatectomy. J Vasc Interv Radiol 22:755–761. CrossRefPubMedPubMedCentral
5.
go back to reference Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol 27:1386–1422. CrossRef Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol 27:1386–1422. CrossRef
7.
go back to reference Gillams AR, Lees WR (2009) Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 19:1206–1213. CrossRefPubMed Gillams AR, Lees WR (2009) Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 19:1206–1213. CrossRefPubMed
8.
go back to reference Wang X, Sofocleous CT, Erinjeri JP et al (2013) Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 36:166–175. CrossRefPubMed Wang X, Sofocleous CT, Erinjeri JP et al (2013) Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 36:166–175. CrossRefPubMed
9.
go back to reference Veltri A, Sacchetto P, Tosetti I et al (2008) Radiofrequency Ablation of Colorectal Liver Metastases: Small Size Favorably Predicts Technique Effectiveness and Survival. Cardiovasc Intervent Radiol 31:948–956.CrossRefPubMed Veltri A, Sacchetto P, Tosetti I et al (2008) Radiofrequency Ablation of Colorectal Liver Metastases: Small Size Favorably Predicts Technique Effectiveness and Survival. Cardiovasc Intervent Radiol 31:948–956.CrossRefPubMed
10.
go back to reference Odisio BC, Yamashita S, Huang SY et al (2017) Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg 104:760–768.CrossRefPubMedPubMedCentral Odisio BC, Yamashita S, Huang SY et al (2017) Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg 104:760–768.CrossRefPubMedPubMedCentral
11.
go back to reference Amado RG, Wolf M, Peeters M et al (2008) Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 26:1626–1634.CrossRefPubMed Amado RG, Wolf M, Peeters M et al (2008) Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 26:1626–1634.CrossRefPubMed
12.
go back to reference Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. N Engl J Med 359:1757–1765. CrossRefPubMed Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. N Engl J Med 359:1757–1765. CrossRefPubMed
13.
go back to reference Pollock CB, Shirasawa S, Sasazuki T et al (2005) Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res 65:1244–1250. CrossRefPubMed Pollock CB, Shirasawa S, Sasazuki T et al (2005) Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res 65:1244–1250. CrossRefPubMed
14.
go back to reference Brudvik KW, Mise Y, Chung MH et al (2016) RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. Ann Surg Oncol 23:2635–2643. CrossRefPubMedPubMedCentral Brudvik KW, Mise Y, Chung MH et al (2016) RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. Ann Surg Oncol 23:2635–2643. CrossRefPubMedPubMedCentral
15.
go back to reference Ahmed M, Solbiati L, Brace CL et al (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. J Vasc Interv Radiol JVIR 25:1691–1705.e4. CrossRefPubMed Ahmed M, Solbiati L, Brace CL et al (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. J Vasc Interv Radiol JVIR 25:1691–1705.e4. CrossRefPubMed
16.
go back to reference Knijn N, Mekenkamp LJM, Klomp M et al (2011) KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104:1020–1026.CrossRefPubMedPubMedCentral Knijn N, Mekenkamp LJM, Klomp M et al (2011) KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104:1020–1026.CrossRefPubMedPubMedCentral
17.
go back to reference Baas JM, Krens LL, Guchelaar H-J et al (2011) Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review. The Oncologist 16:1239–1249.CrossRefPubMedPubMedCentral Baas JM, Krens LL, Guchelaar H-J et al (2011) Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review. The Oncologist 16:1239–1249.CrossRefPubMedPubMedCentral
18.
go back to reference Gillams A, Goldberg N, Ahmed M et al (2015) Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology sans frontières meeting 2013. Eur Radiol 25:3438–3454.CrossRefPubMedPubMedCentral Gillams A, Goldberg N, Ahmed M et al (2015) Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology sans frontières meeting 2013. Eur Radiol 25:3438–3454.CrossRefPubMedPubMedCentral
19.
go back to reference Pathak S, Jones R, Tang JMF et al (2011) Ablative therapies for colorectal liver metastases: a systematic review: Ablation for colorectal liver metastases. Colorectal Dis 13:e252–e265.CrossRefPubMed Pathak S, Jones R, Tang JMF et al (2011) Ablative therapies for colorectal liver metastases: a systematic review: Ablation for colorectal liver metastases. Colorectal Dis 13:e252–e265.CrossRefPubMed
20.
go back to reference Hur H, Ko YT, Min BS et al (2009) Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 197:728–736.CrossRefPubMed Hur H, Ko YT, Min BS et al (2009) Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 197:728–736.CrossRefPubMed
21.
go back to reference Aloia TA (2006) Solitary Colorectal Liver Metastasis: Resection Determines Outcome. Arch Surg 141:460. CrossRefPubMed Aloia TA (2006) Solitary Colorectal Liver Metastasis: Resection Determines Outcome. Arch Surg 141:460. CrossRefPubMed
Metadata
Title
Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival
Authors
Marco Calandri
Suguru Yamashita
Carlo Gazzera
Paolo Fonio
Andrea Veltri
Sara Bustreo
Rahul A. Sheth
Steven M. Yevich
Jean-Nicolas Vauthey
Bruno C. Odisio
Publication date
01-07-2018
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 7/2018
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-017-5273-2

Other articles of this Issue 7/2018

European Radiology 7/2018 Go to the issue